The work reveals how tiny structural shifts can deliver outsize biological effects

Dol-Goy Assist is surprisingly Quinoline Yellow's debut album for respected Manchester label Skam. Although he often appears at live events Dol-Goy Assist is his only his 4th release for the label and...

Dol-Goy Assist is surprisingly Quinoline Yellow's debut album for respected Manchester label Skam. Although he often appears at live events Dol-Goy Assist is his only his 4th release for the label and...

Plants make a surprising intermediate en route to quinine and cinchonidine

New Quinoline Compounds Target Bacterial Energy Production: Ryan Steed discusses their study on whether certain quinoline-based compounds can block the energy system of important antibiotic-resistant…

Cyclopentadienyl (Cp) Ru(IV) quinoline complexes are known for their role in bioorthogonal catalysis within cellular environments, where they use endogenous GSH to deprotect profluorescent and prodrug substrates. However, their reactivity toward GSH and potential for redox-mediated therapies remain underexplored. This study presents RuQ-TARF, a Cp-Ru(IV) complex with a quinoline ligand linked to 2′,3′,4′,5′-tetraacetylriboflavin (TARF) as a redox-active moiety. Its catalytic activity in oxidizing GSH and activating a Pt(IV) prodrug of oxaliplatin was investigated. RuQ-TARF catalyzes the oxidation of GSH to GSSG, improving electron transfer compared to RuQ, its flavin-free analogue. LC–MS analysis showed that activating the Pt(IV) prodrug with GSH produces multinuclear Pt(II)-GS species. RuQ-TARF was additionally evaluated during coincubation with GSH and NADH under blue light, where NADH enabled faster activation of the prodrug, producing oxaliplatin as confirmed by 1H and 195Pt NMR. Cyclic voltammetry showed that linking TARF to RuQ improves the reversibility of redox processes, enhancing catalytic performance and supporting its use in combined GSH oxidation and prodrug activation strategies.

1,540 Australian soldiers were given an unregistered antimalarial. 1,157 more got six times the approved mefloquine dose. No follow-up was ever done.

The SARS-CoV-2 papain-like protease inhibitor, Jun13296, displays potent oral antiviral efficacy in a mouse model of SARS-CoV-2 infection and inhibits SARS-CoV-2 variants and nirmatrelvir-resistant mu...

4-Benzoyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide (1Bz-LSD) and N,N-diethy-7-methyl-4-(4-(trimethylsilyl)benzoyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinolin...